Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
15.28
+1.31 (9.38%)
At close: May 13, 2025, 4:00 PM
14.94
-0.34 (-2.23%)
Pre-market: May 14, 2025, 5:42 AM EDT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $542.71M in the quarter ending March 31, 2025. This brings the company's revenue in the last twelve months to $545.21M, up 1,436.97% year-over-year. In the fiscal year ending September 30, 2024, Arrowhead Pharmaceuticals had annual revenue of $3.55M, down -98.52%.
Revenue (ttm)
$545.21M
Revenue Growth
+1,436.97%
P/S Ratio
3.56
Revenue / Employee
$895,253
Employees
609
Market Cap
2.11B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2024 | 3.55M | -237.18M | -98.52% |
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | Pro | Pro | Pro |
Sep 30, 2018 | Pro | Pro | Pro |
Sep 30, 2017 | Pro | Pro | Pro |
Sep 30, 2016 | Pro | Pro | Pro |
Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ARWR News
- 1 day ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results - Business Wire
- 7 days ago - Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences - Business Wire
- 13 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Is Finally Arriving - Seeking Alpha
- 2 months ago - Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - Business Wire